Updates in hairy cell leukemia (HCL) and variant-type HCL (HCL-V): rationale for targeted treatments with a focus on ibrutinib

Hairy cell leukemia (HCL) and HCL-like disorders such as hairy cell leukemia variant (HCL-V) and splenic diffuse red pulp lymphoma (SDRPL) are rare indolent B-cell malignancies. Purine analogs (PNAs), alone or in association with rituximab (R), are the standard of care for HCL in the first-line sett...

Descripción completa

Detalles Bibliográficos
Autores principales: Paillassa, Jérôme, Safa, Firas, Troussard, Xavier
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9016521/
https://www.ncbi.nlm.nih.gov/pubmed/35450208
http://dx.doi.org/10.1177/20406207221090886

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9016521/
https://www.ncbi.nlm.nih.gov/pubmed/35450208
http://dx.doi.org/10.1177/20406207221090886

Ejemplares similares